Biotechnology

Found 39,832 articles

• Genmab Achieves $50M Sales Milestone in Darzalex Collaboration With Janssen

  11/17/2017

  The milestone was triggered by confirmation by Janssen that sales of Darzalex reached $1 billion in a calendar year.

• 

  Eli Lilly Insulin Drug Price Tripled While Trump's HHS Nominee Was President of the U.S. Unit

  11/17/2017

  Azar, the new HHS nominee, is being pitched as someone who will help lower the price of prescription drugs.

• Acorda Announces Royalty Monetization Transactions for $53M

  11/17/2017

  In return for the payment to Acorda, HCR obtains the right to receive royalty revenue on FAMPYRA payable by Biogen, up to an agreed upon threshold of royalties.

• 

  Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran

  11/17/2017

  This submission allows the FDA to review completed portions of the NDA on an ongoing basis. Alnylam expects to submit final clinical data by year end.

• Array BioPharma Announces Private Exchange of $107M of its 3.00% Convertible Senior Notes Due 2020 for its 2.625% Convertible Senior Notes Due 2024 and Shares of its Common Stock

  11/17/2017

  The Company anticipates that the settlement of the transactions under the exchange agreements will occur on or about December 1, 2017, subject to satisfaction of customary closing conditions.

• Ncardia Announces Completion of 10.5M Euros Investment Round

  11/17/2017

  The round was led by Épimède, a Belgium venture capital firm.

• Patients Who Used Optune More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure's EF-14 Trial

  11/17/2017

  This is a median survival of 24.9 months from randomization and a five-year survival of 29.3 percent.

• Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase II Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan

  11/17/2017

  Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa in the United States.

• Celldex Therapeutics Initiates Phase II Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

  11/17/2017

  The study will enroll approximately 30 patients with cetuximab-resistant, advanced HNSCC who have previously been treated with an anti-PD1 checkpoint inhibitor.

• Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD

  11/17/2017

  Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by Glaxo or one of its affiliates pursuant to its agreements with Innoviva.

• EightSpokes Release: New Peer-to-Peer Feedback Drives Employee Engagement to Improve Work Quality

  11/17/2017

  EightSpokes introduces P2P Feedback with its latest release of Enlighten, the world’s first cloud-based EPC solution.

• Regen BioPharma Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

  11/17/2017

  The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system.

• Sentia Medical Sciences Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases

  11/17/2017

  The new initiative will firstly prioritize gastrointestinal (GI) diseases and endocrine disorders.

• Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

  11/17/2017

  As a result of the merger, Can-Fite’s ownership of OphthaliX, immediately post-merger, became approximately 8% of the outstanding shares.

• Vilacto Bio Inc. Retains Established Independent Investor Relations Firm, The Equity Group Inc.

  11/17/2017

  Vilacto Bio selected The Equity Group due to its 43-year track record of delivering specialized, comprehensive IR programs for small- and mid-sized public companies.

• Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants

  11/17/2017

  Concurrent with this announcement, the Company's CEO will be presenting an overview of its pending Phase IIb Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia on Saturday November 18th, 2017 at 1:30pm ET during the Neuroscience Session at CNS Summit 2017.

• CytRx Corporation Regains Nasdaq Listing Compliance

  11/17/2017

  Separately, CytRx has engaged the services of a third party firm to conduct an in-depth investigation to determine the extent of short-selling in the Company's common stock.

• VBL Therapeutics Prices 2.5 Million Ordinary Share Offering

  11/17/2017

  The offering is subject to customary closing conditions and is expected to close on or about November 21, 2017.

• VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares

  11/17/2017

  The company ntends to use the cash from the offering for the advancement of clinical programs, product development, and for working capital and other general corporate purposes.

• SenesTech Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock

  11/17/2017

  The warrants will have an exercise price of $1.50 per share, are exercisable immediately and will expire five years from the date of issuance.